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Development in an Ovine Model of Placental
Insufficiency-Fetal Growth Restriction
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RUSSELL V. ANTHONY
Department of Biomedical Sciences [A.S.E.H., R.J.O., R.V.A.], Colorado State University, Fort Collins,
CO, 80523; Department of Pediatrics [R.B.W., T.R.H.R., R.V.A.], University of Colorado Health Sciences
Center, Aurora, CO 80045

ABSTRACT
Fetal growth restriction (FGR) is associated with increased
perinatal morbidity and mortality, and often results from functional placental insufficiency. Placentation requires extensive
vasculogenesis and subsequent angiogenesis, in both maternal
and fetal tissues. Angiopoietin-1 (Ang-1) and Angiopoietin-2
(Ang-2) are angiogenic growth factors expressed in the placenta,
and compete for binding to a common receptor, Tunica interna
endothelial cell kinase-2 (Tie-2). Our objective was to examine
Ang-1, Ang-2 and Tie-2 expression in ovine placental tissue
obtained from normal and FGR pregnancies throughout gestation. Fetal cotyledon and maternal caruncle tissue concentrations
of Ang-1, Ang-2 and Tie-2 mRNA were assessed by real-time
reverse transcriptase-polymerase chain reaction and protein concentrations were assessed by Western immunoblot analysis, at
55, 90 and 135 d gestational age (dGA). Concentrations of Ang-1,
Ang-2 and Tie-2 mRNA in FGR fetal cotyledons were increased at
55 dGA, and Tie-2 mRNA concentrations were decreased in FGR
fetal cotyledons and maternal caruncles at 135 dGA. Immunoblot
analysis demonstrated increased concentrations of Ang-2 in the fetal

The placenta is a multifaceted organ that plays the critical
role of maintaining and protecting the developing fetus. A
number of placental structural abnormalities have been associated with fetal growth restriction (FGR), including a decrease
in villous number, diameter and surface area, as well as a
decrease in arterial number, lumen size and branching (1– 6).
All of these abnormalities can adversely affect placental function, and ultimately deprive the fetus of the nutrients required
for optimal growth. Although a variety of factors contribute to
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cotyledon at 55 dGA, and lower concentrations at 135 dGA. In
contrast, concentrations of Tie-2 were increased at 90 dGA, but
tended to decrease at 135 dGA in FGR maternal caruncles. The
changes observed during early- to mid-gestation may result in
increased branching angiogenesis, but may also set the stage for
increased nonbranching angiogenesis during late gestation, altered
placental architecture and placental insufficiency that result in FGR.
(Pediatr Res 58: 1228–1232, 2005)

Abbreviations
Ang, angiopoietin
dGA, days gestational age
FGR, fetal growth restriction
HT, hyperthermia
RT-PCR, reverse transcription-polymerase chain reaction
Tie, tunica interna endothelial cell kinase
TN, thermoneutral
VEGF, vascular endothelial growth factor

a healthy placenta, placental villi form in conjunction with the
developing placental vasculature, thereby providing the main
unit for nutrient exchange (7).
Various approaches have been used to generate animal
models of FGR in several species, including sheep (8). While
placenta in sheep are divided into many discreet attachment
sites or placentomes, within each placentome the villous tree is
structurally similar to that which occurs in the human, as both
can be divided into stem, intermediate and terminal villi (9,10).
In our model, pregnant ewes are exposed to high ambient temperature starting on day 40 of a ⬇147 d gestation, and remain in
this environment for approximately 80 d, resulting in reductions
of placental and fetal weights (12) of approximately 51% and
42%, respectively, near term (135 d gestational age; dGA). Furthermore, these near term pregnancies exhibit fetal hypoxia, hypoglycemia, reduced umbilical blood flow, increased fetal sys-
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temic blood pressure and elevated placental vascular resistance
(8,12,13), the latter being indicative of altered placental vascular
architecture (4). Previously (11,12), we determined that expression of vascular endothelial growth factor (VEGF), placental
growth factor (PlGF), and their receptors (VEGFR-1 and
VEGFR-2) is altered in a gestational age-dependent fashion in
these ovine FGR pregnancies, such that changes that occur during
early- to mid-pregnancy are not mirrored in late gestation. While
the angiopoietins (Ang-1 and Ang-2) are not part of the VEGF
family, they act to potentiate the actions of VEGF. Both Ang-1
and Ang-2 act through their common receptor, Tunica interna
endothelial cell kinase 2 (Tie-2; 14); however, while Ang-1 acts
synergistically with VEGF to simulate angiogenesis (15) by inducing maturation and stabilization of developing vasculature
(16), Ang-2 causes destabilization required for sprout formation
and branching angiogenesis (14). Therefore, our objective was to
examine the expression of Ang-1, Ang-2 and Tie-2 at three
gestational ages in our ovine model of FGR.

METHODS
Experimental animals. Singleton Columbia-Rambouillet ewes approximately 2 to 3 y, at 40 dGA, were placed in either thermoneutral (TN) or
hyperthermic (HT) environments. The TN environment kept a constant ambient temperature of 20 ⫾ 2°C and relative humidity of 30% 24 h per day. The
HT treatment chamber (Bainbridge, Marcellus, MI) controlled ambient temperature of 40°C 12 h per day and 35°C 12 h per day with 30 – 40% relative
humidity. Feed and water intakes were recorded for HT ewes, and TN ewes
were fed the average of HT ewe intake, as previously reported (11,12). Animal
care was approved by the University of Colorado Health Sciences Center
Animal Care and Use Committee, protocol number 56304098 (06)-1F.
Tissue collection. Ewes were killed at either 56 ⫾ 1 dGA, 93 ⫾ 1 dGA or
135 ⫾ 1 dGA, corresponding to 16 d in treatment (dit; TN n ⫽ 6, HT n ⫽ 6),
53 dit (TN n ⫽ 8, HT n ⫽ 6) and 80 dit (TN n ⫽ 4, HT n ⫽ 7), respectively,
as reported (11,12). The 80 dit group were removed from the environmental
chamber at 120 dGA, and maintained under TN conditions until autopsy at 135
dGA. At autopsy, fetal and placental weights were recorded as reported
(11,12), and placentomes were manually separated into fetal cotyledonary and
maternal caruncular components.
Reverse transcriptase-polymerase chain reaction (RT-PCR) and cDNA
preparation. Total cellular RNA (tcRNA) was isolated from ovine cotyledonary and caruncular tissue as previously described (11,12), and resulting tcRNA
concentration was determined by absorbance at A260.
Angiopoietin 1. Published sequences for human (Genbank accession number U83508) and mouse (U83509) Ang-1 were compared and conserved
regions were selected as primers. The upper primer (5=-GGGAGGTTGGACTGTAAT-3=) and lower primer (5=-CTTTATCCCATTCAGTTT-3=) fell within
the coding sequence, and coincided with 1272–1289 bp and 1717–1734 bp of
the human Ang-1 sequence, respectively.
Reverse transcription (RT) was carried out using 1.0 g of tcRNA collected
from 100 dGA ovine cotyledonary tissue. The reaction mixture contained 1
M of the lower Ang-1 specific primer, 0.01 mM DTT, 2 mM dNTP, 2.5 units
of RNase inhibitor and 200 units of recombinant Moloney Murine Leukemia
Virus reverse transcriptase (M-MLV RT) in a 20 L final volume (75 mM
KCl, 3 mM MgCl2 , 50 mM Tris-HCl, pH 8.3). Reactions were incubated for
1 h at 42°C. Subsequent PCR was performed on 5 L of RT product in a
mixture of 0.5 M of each Ang-1 specific primer, 2 mM MgCl2, 0.2 mM dNTP
and 2.5 units of TaqDNA polymerase in a 50 L final volume (50 mM KCl,
20 mM Tris-HCl, pH 8.4). PCR was conducted for 35 cycles at 94, 61 and
72°C 1 min each with a final 10 min extension at 72°C. The PCR product was
inserted into pCR 2.1 and transformed into Inv␣F’ competent cells as described by the manufacturer (Invitrogen Corporation, Carlsbad, CA). The
insert was sequenced (Davis Sequencing, University of California, Davis, CA)
in both directions to verify authenticity, compared with cattle (AF093573),
human and mouse sequences, and the sequence, minus the primers, was
deposited with Genbank (AY881028). This cDNA was used as PCR template,
with new upper (5=-TTGCCATAACCAGTCAGAG-3=) and lower (5=AACCACCAGCCTCCTGTTA-3=) primers, to generate a 259 bp ovine Ang-1
cDNA which was inserted into pCR-Script® (Stratagene, La Jolla, CA),
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sequenced for authenticity, and used for generating real-time RT-PCR standards (see below).
Angiopoietin 2. Published sequences for human (AF004327) and mouse
(AF004326) Ang-2 were compared and conserved regions were selected as
primers. The upper primer (5=-GAAGAAAGAATGTGGCAGAT-3=) fell just
before the coding sequence (341-360 bp) and the lower primer (5=GTCACATGAGGCCTTGATCTC-3=) fell within the coding sequence (1271–
1291 bp). The ovine Ang-2 cDNA was generated by RT-PCR using the same
conditions as for Ang-1, subcloned into pCR2.1, sequenced, compared with
cattle (AF094699), human and mouse sequences, and the sequence, minus the
primers, was deposited with Genbank (AY881029). Sequence analysis revealed that the upper primer annealed to a homologous region (664 – 684 bp of
AF004327) of Ang-2 mRNA, not the region from which the primer was
designed, thereby yielding a 619 bp cDNA (including the primers). This cDNA
was used as PCR template, with new upper (5=-GACCGCTGTGATGATAGAA-3=) and lower (5=-TTTGATTGACCCGAAGTTGA-3=) primers, to generate a 269 bp ovine Ang-2 cDNA which was inserted into pCR-Script®
(Stratagene, La Jolla, CA), sequenced for authenticity, and used for generating
real-time RT-PCR standards (see below).
Tie-2. Primers were designed from the bovine Tie-2 sequence (⫻71424).
The upper (5=-GAGGACAGGCAATAAGGATAC-3=) and lower primers (5=GGAGACAGAACACGAAGGACT-3=) were both located within the coding
sequence (643– 663 bp and 1147–1167 bp, respectively). Two g of tcRNA
collected from 100 dGA ovine fetal brain served as the template for RT-PCR,
under conditions similar to those described for Ang-1, with 35 cycles at 94, 60
and 72°C, 1 min each. The resulting cDNA was inserted into pCR-Script®
(Stratagene, La Jolla, CA), sequenced in both directions (Macromolecular
Resources, Colorado State University, Fort Collins, CO) to verify authenticity,
compared with cattle, human (NM_000459) and mouse (⫻71426) Tie-2
sequences, and the sequence, minus the primers, was deposited with Genbank
(AY881030).
␤-actin. The 498 bp ovine ␤-actin cDNA used in these studies has already
been described (11).
Real-time RT-PCR. Quantitative PCR was carried out using a Bio-Rad
iCycler® (Hercules, California). PLATINUM Quantitative PCR SUPERMixUDG (1.5U PLATIMUM TaqDNA polymerase, 20 mM Tris-HCl (pH 8.4), 50
mM KCl, 3 mM MgCl2, 200 M dGTP, 200 M dATP, 200 M dCTP, 200
M dUTP, 1U UDG) was the base for the master mix. To determine the
optimum MgCl2 concentration for each amplicon, identical samples were
amplified in the presence of either 3 mM, 4 mM, 5 mM or 6 mM MgCl2. The
2⫻ Platinum® Quantitative PCR SuperMix-UDG (GIBCO BRL® ) contains
a final MgCl2 concentration of 3 mM, and the reactions were adjusted
accordingly with 50 mM MgCl2. The reaction closest to a line with the slope
of –3.322 (which is considered 100% efficiency for the iCycler®) was identified, and the corresponding MgCl2 concentration was used for that particular
amplicon. The predetermined MgCl2 concentration was then added to the
master mix of 0.2 M forward primer, 0.2 M reverse primer, 0.2 M
SYBR® Green I (Molecular Probes, Eugene, OR), 2⫻ Platinum® Quantitative
PCR SuperMix-UDG (GIBCO BRL®) and volumed to 40 L with PCR grade
H20 (Ambion Inc.).
To the seven standard reactions, 10 L of control template was added to 40
L of master mix. To make the standards, a 10-fold dilution series was
prepared of sample template (Ang-1, Ang-2, Tie-2 or ␤-actin cDNA) from 10
to 10⫺5 pg/10 L. For the samples of unknown amplicon, 5 L RT (as
described previously) and 5 L PCR grade H20 (Ambion Inc.) was added to 40
L of master mix. When the RT reactions were prepared for either cotyledon
or caruncle of each animal in all treatment groups, the quantity was adjusted
to allow the same RT reaction to be used for Ang-1, Ang-2, Tie-2 and ␤-actin
amplification.
Finally, 50 L reactions were mixed, and aliquoted into 96-well PCR plates
(Bio-Rad). Before running each PCR reaction, an external Well Factor (BioRad) plate was used to calibrate the iCycler®, adjust for any imperfections in
mirrors and collect background data. PCR conditions were 5 min at 95°C
followed by 45 cycles of 20 s at 95°C, 1 min at optimal annealing temperature
(Ang-1, 57°C; Ang-2, 57°C; Tie-2, 60°C; ␤-Actin, 55°C), followed by 1 min
at 72°C. Fluorescent data were collected by the iCycler® during the optimal
annealing step for real time analysis. Reproducibility of the real-time RT-PCR
data were evaluated by determining an intra-assay coefficient of variation for
a high, middle and low set of standards for each amplicon. The average
correlation coefficients and slopes for each Ang-1, Ang-2, Tie-2 and ␤-actin
PCR, as well as for all runs included in the data set, were compared with the
correlation coefficient and slope representing 100% efficiency for the iCycler®
as determined by BioRad® and expressed as mean⫾ SEM.
Southern blot analysis. Real-time RT-PCR products were electrophoresed
through 1% Agarose gels and capillary blotted onto nylon membranes. Asymmetric PCR was used to generate dCTP-32P labeled cDNAs encoding Ang-1,
Ang-2, Tie-2 and ␤-actin. The denatured, PCR generated cDNA was added to
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membranes at a concentration of 2– 4 ⫻ 106 cpm/mL and incubated overnight
at 42°C. Membranes were then washed and exposed to Kodak x-ray film to
verify hybridization of real-time RT-PCR product.
Protein extraction and western blot analysis. Tris-based lysis buffer (0.48
M Tris (pH 7.4), 10 mM EGTA, 10 mM EDTA, 0.1% vol/vol BME, Protease/
phosphatase Inhibitor cocktail (Sigma Chemical Co.), 0.1 mM AEBSF, 2.0
M Leupeptin, 1.5 M Pepstatin, 1.4 M E64, 4.0 M Bestatin, 0.08 M
Aprotinin, 0.1 mM PMSF) was added to 100 mg of either cotyledonary or
caruncular tissue, sonicated, and the resulting protein concentration was quantified by Bradford assay. Proteins were separated using 10% Tris-HCl gels
(BioRad) for Ang-1 and Ang-2, or 7.5% Tris-HCl gels Tie-2, and subjected to
Western Blot analysis as previously described (11,12). Detection of Ang-1
(sc-6320), Ang-2 (sc-7015), Tie-2 (sc-324) and Actin (sc-1615) was accomplished by incubating in the presence of a 1:1000 dilution of primary antiserum
(Santa Cruz Biotechnology), followed by incubation with anti-goat IgG
(Ang-1, Ang-2 and Actin) or anti-rabbit IgG (Tie-2) horseradish peroxidase
conjugated secondary antibody (Santa Cruz Biotechnology) at 1:20,000. Following incubation in Supersignal West Femto Maximum Sensitivity Substrate
(Pierce Chemical Co., Rockford, IL), the membranes were exposed to Kodak
x-ray film. Protein quantification was accomplished using ImageQuant (Molecular Dynamics). Specific blocking peptides (Santa Cruz Biotechnology)
were used to verify authenticity of detection.
Statistical analysis. Concentrations of Ang-1, Ang-2 and Tie-2 mRNA and
protein were normalized on the respective ␤-actin concentration, and normalacy of the data were tested with a two-tailed F test. Between treatment
comparisons for either cotyledonary or caruncular tissue within the same
gestational age (day 55 TN vs. day 55 HT, day 90 TN vs. day 90 HT, and day
135 TN vs. day 135 HT) were compared by Student’s t test, and are presented
as mean⫾ SEM. A p-value ⱕ 0.05 was considered statistically significant.

RESULTS
Generation of Ovine cDNAs. Using RT-PCR, partial cDNAs
for ovine Ang-1, Ang-2 and Tie-2 were generated and sequenced. The 427 bp ovine Ang-1 sequence exhibited 98, 92
and 88% sequence identity with cattle, human and mouse
Ang-1 sequences, respectively. The 578 bp ovine Ang-2 cDNA
shared 94, 85 and 79% nucleotide sequence identity with cattle,
human and mouse Ang-2, respectively, and the ovine Tie-2
(483 bp) sequence exhibited 97, 92 and 89% sequence identity
with cattle, human and mouse Tie-2.
Real-time RT-PCR. Utilizing these cDNAs, mRNA expression was evaluated in 55, 90 and 135 dGA placental tissue by
real-time RT-PCR. The placental and fetal characteristics of
these pregnancies have been previously reported (11,12). There
was a 36% reduction in placental weight and a 27% reduction
in fetal weight at 90 dGA gestational age (11), and reductions
of placental and fetal weights (12) of approximately 51% and
42%, respectively, at 135 dGA. The intra-assay coefficient of
variation for Ang-1, Ang-2, Tie-2 and ␤-actin mRNA determinations by real-time RT-PCR was 1.94%, 1.23%, 1.64% and
1.28% respectively. Expression of Ang-1 in the maternal caruncle was not significantly (p ⱖ 0.10) affected by treatment, at
any of the gestational ages examined (Fig. 1). However, Ang-1
mRNA concentration was significantly (p ⱕ 0.05) increased at
55 dGA in HT fetal cotyledons, but remained unchanged (p ⱖ
0.10) at 90 and 135 dGA (Fig. 1). Angiopoietin-2 mRNA
showed a similar expression pattern as Ang-1 mRNA, with no
effect (p ⱖ 0.10) of treatment at any gestational age in the
maternal caruncle, but a significant (p ⱕ 0.05) increase in 55 dGA
fetal cotyledons from HT pregnancies (Fig. 2). Real-time RT-PCR
analysis of maternal caruncular tissue for Tie-2 revealed that
mRNA concentration was significantly (p ⱕ 0.05) decreased at
135 dGA in HT pregnancies, but there were no significant (p ⱖ
0.10) changes at 55 or 90 dGA due to treatment (Fig. 3). However,
Tie-2 mRNA concentration was significantly (p ⱕ 0.01) increased

Figure 1. Relative concentrations of ovine Ang-1 mRNA at 55, 90 and 135 d
of gestation in an ovine model of FGR. Ovine Ang-1 mRNA concentrations in
the maternal caruncle (A) and fetal cotyledon (B), were determined by realtime RT-PCR and normalized on ␤-actin mRNA concentrations, for both TN
(shaded columns) and HT (black columns) pregnancies at 55 (TN n ⫽ 6, HT
n ⫽ 6), 90 (TN n ⫽ 8, HT n ⫽ 6) and 135 (TN n ⫽ 4, HT n ⫽ 7) dGA. * p
ⱕ 0.05, comparison between TN and HT, within gestational age.

Figure 2. Relative concentrations of ovine Ang-2 mRNA at 55, 90 and 135 d
of gestation in an ovine model of FGR. Ovine Ang-2 mRNA concentrations in
the maternal caruncle (A) and fetal cotyledon (B), were determined by realtime RT-PCR and normalized on ␤-actin mRNA concentrations, for both TN
(shaded columns) and HT (black columns) pregnancies at 55 (TN n ⫽ 6, HT
n ⫽ 6), 90 (TN n ⫽ 8, HT n ⫽ 6) and 135 (TN n ⫽ 4, HT n ⫽ 7) dGA. * p
ⱕ 0.05, comparison between TN and HT, within gestational age.

Figure 3. Relative concentrations of ovine Tie-2 mRNA at 55, 90 and 135 d
of gestation in an ovine model of FGR. Ovine Tie-2 mRNA concentrations in
the maternal caruncle (A) and fetal cotyledon (B), were determined by realtime RT-PCR and normalized on ␤-actin mRNA concentrations, for both TN
(shaded columns) and HT (black columns) pregnancies at 55 (TN n ⫽ 6, HT
n ⫽ 6), 90 (TN n ⫽ 8, HT n ⫽ 6) and 135 (TN n ⫽ 4, HT n ⫽ 7) dGA. * p
ⱕ 0.05; ** p ⱕ 0.01, comparison between TN and HT, within gestational age.

at 55 dGA and significantly (p ⱕ 0.01) depressed at 135 dGA in
fetal cotyledons from HT pregnancies, but was unaffected by
treatment at 90 dGA (Fig. 3).
Western blot analysis. Tissue protein concentrations of
Ang-1, Ang-2 and Tie-2 were determined in ovine placental
tissue at 55, 90 and 135 dGA for both treatments, and the data
were normalized on ␤-actin concentrations. Single bands were
detected for each protein with the antibodies used, and their
authenticity verified by preincubation with blocking peptides.
Ang-1 and Ang-2 had apparent molecular weights of approximately 55,000 (Fig. 4 and 5), whereas the apparent molecular
weight of Tie-2 was approximately 150,000 (Fig. 6). Tissue
concentrations of ovine Ang-1 were not significantly (p ⱖ
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Figure 4. Relative concentrations of ovine Ang-1 at 55, 90 and 135 d of
gestation in an ovine model of FGR. A representative Western blot for
Ang-1for 135 dGA cotyledon samples is presented in the top panel (A) along
with the apparent molecular weight of the immunoreactive bands. Ovine Ang-1
concentrations in the maternal caruncle (B) and fetal cotyledon (C), were
determined by Western blot analysis and normalized on ␤-actin concentrations, for
both TN (shaded columns) and HT (black columns) pregnancies at 55 (TN n ⫽ 6,
HT n ⫽ 6), 90 (TN n ⫽ 8, HT n ⫽ 6) and 135 (TN n ⫽ 4, HT n ⫽ 7) dGA. No
statistical differences were found.

Figure 5. Relative concentrations of ovine Ang-2 at 55, 90 and 135 d of gestation
in an ovine model of FGR. A representative Western blot for Ang-2 for 135 dGA
cotyledon samples is presented in the top panel (A) along with the apparent
molecular weight of the immunoreactive bands. Ovine Ang-2 concentrations in the
maternal caruncle (B) and fetal cotyledon (C), were determined by Western blot
analysis and normalized on ␤-actin concentrations, for both TN (shaded columns)
and HT (black columns) pregnancies at 55 (TN n ⫽ 6, HT n ⫽ 6), 90 (TN n ⫽
8, HT n ⫽ 6) and 135 (TN n ⫽ 4, HT n ⫽ 7) dGA. * p ⱕ 0.05, ** p ⱕ 0.01,
comparison between TN and HT, within gestational age.

0.10) affected by treatment or tissue type at any gestational age
(Fig. 4). However, ovine Ang-2 concentration tended (p ⱕ
0.10) to be lower in HT caruncular tissue at 135 dGA (Fig. 5).
In the fetal cotyledon, concentration of Ang-2 was increased at
55 dGA (p ⱕ 0.05), but tended (p ⱕ 0.10) to be lower at 90
dGA, and was significantly less in 135 dGA (p ⱕ 0.01) HT
fetal cotyledons (Fig. 5). Tie-2 concentration was not significantly altered at 55 dGA in the maternal caruncle, but was
significantly increased (p ⱕ 0.05) at 90 dGA and tended (p ⱕ
0.10) to be less in 135 dGA HT pregnancies (Fig. 6). Fetal
cotyledon Tie-2 concentration was not significantly altered by
treatment at any gestational age (Fig. 6).
DISCUSSION
Placental development begins early in pregnancy, and continues throughout gestation, as increased blood supply to, and
vascular development within, the placentas are required to
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Figure 6. Relative concentrations of ovine Tie-2 at 55, 90 and 135 d of
gestation in an ovine model of FGR. A representative Western blot for Tie-2
for 135 dGA cotyledon samples is presented in the top panel along with the
apparent molecular weight of the immunoreactive bands. Ovine Tie-2 concentrations in the maternal caruncle (B) and fetal cotyledon (C), were determined
by Western blot analysis and normalized on ␤-actin concentrations, for both
TN (shaded columns) and HT (black columns) pregnancies at 55 (TN n ⫽ 6,
HT n ⫽ 6), 90 (TN n ⫽ 8, HT n ⫽ 6) and 135 (TN n ⫽ 4, HT n ⫽ 7) dGA.
* p ⱕ 0.05, comparison between TN and HT, within gestational age.

support the needs of the growing fetus. The importance of
these processes becomes obvious when placental development
is perturbed, leading to functional placental insufficiency and
FGR. In the present study, we examined placental expression
of Ang-1, Ang-2 and Tie-2 in an ovine model of FGR that
results from placental growth restriction (11–13). At 55 dGA,
Ang-1, Ang-2 and Tie-2 mRNA concentrations were elevated
in the fetal cotyledon, but only Ang-2 protein concentration
was increased and there were no expression differences in the
maternal caruncle. These data agree with our previous report
(11) of increased VEGF mRNA at 55 dGA in FGR pregnancies, and may be a function of altered blood flow in response
to the hyperthermic environment. Uteroplacental blood flow
has been reported to fall following exposure to hyperthermia
during mid-pregnancy (80 dGA), and persisted throughout the
20 d treatment period (17), potentially generating a hypoxic
environment for placental development. However, potential
changes in uteroplacental blood flow and oxygen uptake have
not been evaluated using our current paradigm. Elevated expression of VEGF (11), Ang-1, Ang-2 and Tie-2 may be an
adaptive response to this environment, in an attempt to maintain placental development, but may also adversely program
the placenta for functional insufficiency later in gestation, by
altering the trajectory or pattern of placental vascular development. At 90 dGA, the only significant change in expression
occurred with Tie-2, and while Tie-2 protein concentration was
elevated in the maternal caruncle, no differences were found in
maternal caruncle Tie-2 mRNA concentration or in fetal cotyledon mRNA or protein concentration. It is interesting to note
that at this stage of gestation, fetal cotyledon PlGF, VEGFR-1
and VEGFR-2 mRNA concentrations are reduced (11). While
the significance of these changes is not easily discernible, they
may indicate that this is a period of transition toward the end
of the second third of gestation between the acute responses
and those observed with late gestational placental insufficiency.
Near-term (135 dGA), we observed reductions in Tie-2
mRNA concentration within the maternal caruncle and fetal
cotyledon, as well as reduced Ang-2 protein concentrations in the
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fetal cotyledon with no statistical differences in mRNA concentration. The Ang-2 data agree with the report by Dunk et al. (18)
with human FGR pregnancies, characterized by absent end diastolic umbilical flow velocities, in that placental Ang2 concentration is depressed without coordinate reductions in Ang2 mRNA.
Dunk et al. (18) suggest that this may result from a failure of
translational regulatory mechanism in these FGR pregnancies.
Previously we reported reduced VEGF mRNA and protein concentrations and reduced VEGFR-1 mRNA concentration in the
fetal cotyledon of 135 dGA FGR pregnancies, whereas maternal
caruncle PlGF mRNA and protein were elevated (12). Hypoxia is
known to stimulate VEGF expression (19), and both hypoxia and
VEGF stimulate Ang-2 expression (20). While the near-term
fetuses in our study were hypoxic (12), maternal uterine blood
flow and uterine venous PO2 were increased, leading to a greater
transplacental PO2 gradient, consistent with the concept of postplacental hypoxia (21) in severe FGR.
Development of the placental vascular network begins early,
with an initial phase of vasculogenesis, followed by branching
and then nonbranching angiogenesis (22). Whereas VEGF promotes both vasculogenesis and angiogenesis within the placenta
(23), the angiopoietins likely only play a role in angiogenesis (24).
Both Ang-1 and Ang-2 interact with the receptor Tie-2 (14) with
equal affinity, and while Ang-1 induces maturation and stabilization of the developing vasculature (25), Ang-2 causes destabilization required for additional sprout formation and branching
angiogenesis (14).
Within the human placenta, Ang-2 expression is greatest
during the first trimester, and wanes as gestation progresses
(26,27). Greater expression of Ang-2 during the first trimester,
with Ang-1 and VEGF expression increasing from early to late
gestation (27), fits with the concept that branching angiogenesis occurs during early placental development, followed by
nonbranching angiogenesis (22). In the present study, the
reductions in Ang-2 and Tie-2 coincide with reductions in
VEGF and VEGFR-1 along with elevated PlGF (12), suggesting a disposition toward increased nonbranching angiogenesis
in our near-term FGR pregnancies.
With the current data for the angiopoietins and their receptor, our earlier studies of VEGF, PlGF and their receptors
(11,12), along with reports by others (18), discordance between
tissue mRNA and protein concentrations is observed. These
apparent discordant responses may well result from singlepoint in time measurements, or the fact that when measuring
tissue concentrations of a protein, one cannot discern between
intracellular stores, protein associated with extracellular matrix
or specific receptors, or determine the degradation rate following receptor binding. It is possible that posttranscriptional
regulation of all of these angiogenic growth factors and their
receptors, such as has been documented for VEGF (28,29)
could explain these discrepancies. Regardless, these data
clearly define that changes in angiogenic growth factor expression during the first two-thirds of gestation is quite different
from those observed near-term. The early changes may well
occur as a compensatory mechanism, but in turn set the stage
for increased nonbranching angiogenesis, altered placental architecture and functional placental insufficiency that result in
FGR during late gestation.
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